Happy National Nanotechnology Day from Clene Nanomedicine! Today, we celebrate the many improvements that #nanotechnology can make in our lives. Learn more about our #nano-therapeutics: bit.ly/3J9LcbH $CLNN

#ICYMI: Our very own Karen Ho, PhD, (Karen Ho now on BlueSky) shared her experience transitioning from academic to biotech research and spelled out $CLNN 's vision for treating neurodegenerative diseases with nanoparticle-based therapeutics. Check it out: bit.ly/3yeU6VM

#ICYMI: Merit Cudkowicz, MD, MSc, Robert P. Bowser, Ph.D., and $CLNN Head of Medical Benjamin Greenberg, MD, MHS, FAAN, presented an update on the long-term data for #CNMAu8 in a NEALS Consortium webinar. Watch now: bit.ly/3YhTMhY

Neuronal energy deficits occur in neurodegenerative diseases like #ALS, resulting in neuronal dysfunction and death. Our nanotherapeutic #CNMAu8 supports energy production in neurons to help restore healthy neuron function. Learn more: bit.ly/3VrtSs0 $CLNN #EndALS

#DYK? About 90% of people diagnosed with #ALS have no known family history of or genetic cause for this debilitating disease. Learn more from The ALS Association to increase your #ALSawareness: bit.ly/3e3BsCk

$CLNN’s CEO Rob Etherington and CSO Mark Mortenson recently presented how the novel nanomedicine #CNMAu8 performed in Phase 2 clinical trials, demonstrating survival benefits and safety in #ALS with Buck Joffey on the @SapioPodcast. Tune in here: youtu.be/5tg6R_Cv9_U

Marjan Sepassi, PharmD, of Clene Nanomedicine ($CLNN) will present “CNM-Au8 Long-term Evidence and EAP Program Update” tomorrow, December 4, 2024 at 4 PM PT / 7 PM ET at the next #ALSExpertTalks hosted by EverythingALS. Register here: everythingals.org/events #EndALS #ALS #CNMAu8

TODAY: Don't miss the $CLNN update from Marjan Sepassi, PharmD, on the development program for #CNMAu8 for #ALS! Register here: everythingals.org/events

Clene Nanomedicine, Inc. (NASDAQ: $CLNN) is thrilled to be presenting four posters on the long-term safety and efficacy of #CNMAu8 in treating #ALS at the 35th International #alssymp in Montreal, Canada, Dec. 6-8. Come talk to us during Poster Sessions A and B! #EndALS

FDA provides Clene Nanomedicine (NASDAQ:$CLNN) with feedback on a potential accelerated approval pathway for CNM-Au8® For today’s Press Release of Dec. 10, 2024 see: globenewswire.com/news-release/2…

The FDA may grant accelerated approval for a new ALS therapy after data showed reduced nerve damage markers and improved survival rates. Learn more here: bit.ly/3ORaUqU #ALS #AmyotrophicLateralSclerosis #ALSDisease #ALSTreatment #ALSResearch

Clene Nanomedicine ($CLNN) announces the signing of a new debt facility with an aggregate total of $10M, proceeds from which will be used to analyze new data on #CNMAu8 to treat #ALS. Data will support an NDA via an accelerated approval pathway. Read more: invest.clene.com/news-releases/…

Clene Nanomedicine, with APST, will utilize one of the largest, most comprehensive longitudinal #ALS data repositories to analyze changes in levels of the biomarker #NfL with #CNMAu8 treatment, supporting a recommendation from the FDA. READ MORE: invest.clene.com/news-releases/…

A cross-regimen analysis of Regimens A and C of the Healey ALS Platform Trial revealed new evidence of a survival benefit with Clene Nanomedicine’s novel nanocatalytic drug, #CNMAu8, confirming existing survival benefit results and biomarker data: invest.clene.com/news-releases/…

DON’T MISS Jeremy Evan, Pharmacovigilance Manager of Clene Nanomedicine, on the “Therapeutic Modulation of Brain Energy Metabolites by #CNMAu8, a Suspension of Catalytically Active Gold Nanocrystals.” He presents at the 64th Annual Society of Toxicology in Orlando, Fl on Monday, March 17!

TODAY Jeremy Evan, Pharmacovigilance Manager of Clene Nanomedicine, presents “Therapeutic Modulation of Brain Energy Metabolites by #CNMAu8, a Suspension of Catalytically Active Gold Nanocrystals” at the 64th Annual Society of Toxicology in Orlando, Fl on Monday, March 17! See you there!

Dr. Ben Greenberg of Clene Nanomedicine will present on “Physiologic and Anatomical Evidence of Neuronal Repair and Remyelination” by #CNMAu8 in #multiplesclerosis at #AANAM 2025. See you at the Late-breaking Science 2 Session on Tuesday, April 8, 5:45 p.m. and at Poster 3!

TODAY Dr. Ben Greenberg of Clene Nanomedicine will present on “Physiologic and Anatomical Evidence of Neuronal Repair and Remyelination” by #CNMAu8 in #multiplesclerosis at #AANAM 2025! See you tonight at the Late-breaking Science 2 Session on Tuesday, April 8, 5:45 p.m. and at Poster 3!

Cool news! A Clene Nanomedicine article received enough views to be a Top Viewed Article in the peer-reviewed journal Small. Read it here onlinelibrary.wiley.com/doi/full/10.10… #TopViewedArticle Wiley in research